Literature DB >> 14550466

Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury.

Sharon R Inman1, Nancy A Davis, Kristen M Olson, Victoria A Lukaszek, Marc R McKinley, Jennifer L Seminerio.   

Abstract

OBJECTIVES: To determine the effect of cyclosporine and rapamycin administration on renal function after ischemia/reperfusion injury (I/R). Cyclosporine A has known nephrotoxic effects. Thus, cyclosporine therapy subsequent to I/R injury may further exacerbate graft dysfunction. Rapamycin is a newer agent that suppresses the immune system by a different mechanism.
METHODS: Male Wistar rats (250 g) were anesthetized, and the suprarenal aorta was clamped for 40 minutes. The right kidney was removed. After recovery, the rats were divided into four groups: group 1, controls, no ischemia and no treatment (n = 10); group 2, ischemia with no treatment (n = 8); group 3, ischemia plus rapamycin (0.17 mg/kg/day gavage, n = 8); and group 4, ischemia plus cyclosporine A (30 mg/kg/day intraperitoneally, n = 9). The glomerular filtration rate was measured 5 to 7 days after I/R injury using urinary iohexol clearance. Data are expressed as the mean +/- SEM, and intergroup comparisons were made using one-way analysis of variance.
RESULTS: The mean GFR value for the controls (no ischemia, no treatment) was 1.23 +/- 0.08 mL/min; for group 2 (ischemia, no treatment), it was 1.05 +/- 0.10 mL/min; for group 3 (ischemia plus rapamycin) 1.06 +/- 0.14 mL/min; and for group 4 (ischemia plus cyclosporine A) 0.44 +/- 0.06 mL/min (P <0.05 versus the other three groups). The mean arterial pressure was significantly lower in the ischemic rats treated with cyclosporine A (P <0.05 versus the other three groups).
CONCLUSIONS: After I/R injury, rapamycin may preserve renal function compared with cyclosporine treatment, because it does not have a direct vasoconstrictor effect on the renal microcirculation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14550466     DOI: 10.1016/s0090-4295(03)00475-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

1.  Rapamycin protection of livers from ischemia and reperfusion injury is dependent on both autophagy induction and mammalian target of rapamycin complex 2-Akt activation.

Authors:  Jianjun Zhu; Tianfei Lu; Shi Yue; Xiuda Shen; Feng Gao; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Qiang Xia; Yuan Zhai
Journal:  Transplantation       Date:  2015-01       Impact factor: 4.939

Review 2.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

3.  Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model.

Authors:  F Cicora; J Roberti; D Vasquez; D Guerrieri; N Lausada; P Cicora; G Palti; E Chuluyan; P Gonzalez; P Stringa; C Raimondi
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

4.  Sirolimus attenuates reduced-size liver ischemia-reperfusion injury but impairs liver regeneration in rats.

Authors:  Yuan-Xing Liu; Li-Ming Jin; Lin Zhou; Hai-Yang Xie; Guo-Ping Jiang; Hui Chen; Shu-Sen Zheng
Journal:  Dig Dis Sci       Date:  2009-10-24       Impact factor: 3.199

5.  Rapamycin suppresses hypoxia/reoxygenation-induced islet injury by up-regulation of miR-21 via PI3K/Akt signalling pathway.

Authors:  Yi Zhang; Sirong He; Xiaojion Du; Yaowen Jiang; Bole Tian; Shuyun Xu
Journal:  Cell Prolif       Date:  2016-09-29       Impact factor: 6.831

6.  The effects of sirolimus on target organs during mesenteric ischemia and reperfusion damage in an experimental rat model.

Authors:  Tamer Sagiroglu; Atakan Sezer; Semsi Altaner; Hasan Umit; Tulin Yalta; Mehmet Ali Yagci
Journal:  Curr Ther Res Clin Exp       Date:  2011-04

Review 7.  Sirolimus-associated proteinuria and renal dysfunction.

Authors:  Gopala K Rangan
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

8.  Rapamycin Alternatively Modifies Mitochondrial Dynamics in Dendritic Cells to Reduce Kidney Ischemic Reperfusion Injury.

Authors:  Maria Namwanje; Bijay Bisunke; Thomas V Rousselle; Gene G Lamanilao; Venkatadri S Sunder; Elizabeth C Patterson; Canan Kuscu; Cem Kuscu; Daniel Maluf; Manjari Kiran; Valeria Mas; James D Eason; Amandeep Bajwa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

9.  Protective role of p70S6K in intestinal ischemia/reperfusion injury in mice.

Authors:  Kechen Ban; Rosemary A Kozar
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling.

Authors:  Steven T Haller; Yanling Yan; Christopher A Drummond; Joe Xie; Jiang Tian; David J Kennedy; Victoria Y Shilova; Zijian Xie; Jiang Liu; Christopher J Cooper; Deepak Malhotra; Joseph I Shapiro; Olga V Fedorova; Alexei Y Bagrov
Journal:  J Am Heart Assoc       Date:  2016-09-30       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.